Distribution of antihistamines into the CSF following intranasal delivery.
The preferential absorption of certain drug compounds from the nasal cavity into the cerebrospinal fluid (CSF) raises questions regarding the transport processes controlling drug disposition following intranasal delivery. The disposition characteristics of several structurally similar antihistamine compounds, hydroxyzine, chlorpheniramine, triprolidine, and chlorcyclizine, into the CSF following nasal administration were studied using the rat as an animal model. The antihistamines were administered either intranasally or intra-arterially, and serial CSF and plasma samples were collected from the cisterna magna and the femoral artery, respectively. The drug levels in CSF and plasma were assayed by HPLC. Hydroxyzine concentrations in plasma and CSF were found to be significantly greater than most of the other compounds tested. In addition, hydroxyzine also showed the most rapid systemic absorption following nasal administration. Interestingly, the hydroxyzine levels in CSF following intranasal administration were significantly higher than those following intra-arterial administration. The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively. The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively. The distribution of antihistamines from the nasal membrane into the CSF appears to be controlled by a combination of their molecular properties. It also appears that the intranasal delivery of drugs with optimal physicochemical characteristics can result in an improved CNS bioavailability compared to those achieved from an equivalent parenteral dose.
Chou
K J
KJ
College of Pharmacy, University of Iowa, Iowa City 52242, USA.
Donovan
M D
MD
D000281:Administration, Intranasal; D000818:Animals; D001692:Biological Transport; D001798:Blood Proteins / Q000378:metabolism; D002744:Chlorpheniramine / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics; D006919:Hydroxyzine / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D007269:Injections, Intra-Arterial; D008297:Male; D009296:Nasal Cavity / Q000378:metabolism*; D010879:Piperazines / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship; D014018:Tissue Distribution; D014311:Triprolidine / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics
D001798:Blood Proteins; D006634:Histamine H1 Antagonists; D010879:Piperazines; D014311:Triprolidine; D006919:Hydroxyzine; D002744:Chlorpheniramine; C084597:chlorcyclizine